Document is current
Any future updates will be listed below
-
Authors
Selvaggi, Pierluigi https://orcid.org/0000-0001-9069-0700
Osugo, Martin https://orcid.org/0000-0002-5462-8464
Zahid, Uzma
Dipasquale, Ottavia
Whitehurst, Thomas https://orcid.org/0000-0002-7005-902X
Onwordi, Ellis
Chapman, George
Finelli, Valeria
Statton, Ben https://orcid.org/0000-0001-5118-7977
Wood, Tobias C.
Wall, Matthew B.
Murray, Robin https://orcid.org/0000-0003-0829-0519
Mehta, Mitul A. https://orcid.org/0000-0003-1152-5323
Marques, Tiago Reis https://orcid.org/0000-0003-0602-7661
Howes, Oliver D. https://orcid.org/0000-0002-2928-1972
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (964874)
South London and Maudsley NHS Foundation Trust
RCUK | Medical Research Council (MC_U120097115)
Maudsley Charity (666)
Wellcome Trust (094849/Z/10/Z)
- License Information
-
More Information
Article History
Received: 25 February 2025
Revised: 6 April 2025
Accepted: 24 April 2025
First Online: 7 May 2025
Competing interests
: In the past three years, MAM has been an advisory board member for Lundbeck and Forum Pharmaceuticals. He also received research funding from Lundbeck, Takeda, and Johnson & Johnson. O.D.H. has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lundbeck, Merck, Neurocrine, Ontrack/ Pangea, Otsuka, Sunovion, Recordati, Roche, Rovi and Viatris/Mylan. He was previously a part-time employee of Lundbeck A/v. Neither O.D.H. nor his family have holdings/a financial stake in any pharmaceutical company. ODH has a patent for the use of dopaminergic imaging. PS participated in advisory/speaker meetings organized by Angelini and Lundbeck. M.B.W. is an employee of Perceptive Inc., London. T.R.M. is an employee and founder of Pasithea Therapeutics. Other authors have reported no biomedical financial interests or potential conflicts of interest.
